Chandra Bhagat Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Chandra Bhagat Pharma Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $2.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Chandra Bhagat Pharma Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $2.0M Trade | TransData Nexus

Chandra Bhagat Pharma Limited

Indian Pharmaceutical Exporter · Other Specialist · $2.0M Total Trade · DGFT Verified

Chandra Bhagat Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $2.0M across 9 products in 6 therapeutic categories. Based on 81 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Immunoglobulin ($950.0K), Trastuzumab ($300.0K), Guaifenesin ($283.1K).

Chandra Bhagat Pharma Limited — Export Portfolio & Destination Treemap

Chandra Bhagat Pharma Limited pharmaceutical export portfolio — 9 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Chandra Bhagat Pharma Limited? — Company Overview & Market Position

Chandra Bhagat Pharma Limited, established in 1944, is a Mumbai-based pharmaceutical company specializing in the marketing of critical care and healthcare products both domestically and internationally. The company offers a diverse range of pharmaceutical formulations, including intravenous and intramuscular injections, tablets, and capsules, across various therapeutic categories such as oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, and more. These products are distributed under the company's own brand to hospitals and healthcare centers.

Incorporated as a private limited company on March 10, 2003, Chandra Bhagat Pharma Limited transitioned to a public limited company on March 20, 2019. The company's authorized capital stands at ₹85 million, with a paid-up capital of ₹75.45 million. As of January 10, 2026, the company employs approximately 40 individuals. The registered office is located at 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai, Maharashtra, India, 400019.

What Does Chandra Bhagat Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$950.0K

Product Portfolio — Top 9 by Export Value

Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$950.0K	19	0.5%	7
2	Trastuzumab	Advanced Oncology	$300.0K	6	0.4%	7
3	Guaifenesin	Respiratory & OTC	$283.1K	9	1.1%	13
4	Cyclosporine	Immunosuppressants	$156.2K	12	1.3%	10
5	Warfarin	Cardiovascular	$139.3K	16	1.9%	7
6	Fosfomycin	Advanced Antibiotics	$85.5K	4	0.7%	7
7	Fludarabine	Advanced Oncology	$24.3K	4	0.8%	7
8	Actinomycin	Advanced Oncology	$19.2K	6	0.7%	11
9	Mitoxantrone	Advanced Oncology	$18.3K	5	1.0%	5

Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories with a total export value of $2.0M. The top category is Other (48.1% of portfolio), followed by Advanced Oncology (18.3%), indicating a concentrated portfolio with the top 5 products accounting for 92.5% of total export value.

Chandra Bhagat Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Chandra Bhagat Pharma Limited operates manufacturing facilities through contract manufacturing arrangements, focusing on the production of pharmaceutical formulations. The company specializes in a range of products, including intravenous and intramuscular injections, tablets, and capsules, catering to both domestic and international markets. By outsourcing manufacturing to third-party contract manufacturers, Chandra Bhagat Pharma Limited ensures compliance with regulatory standards and maintains flexibility in production capacity.

3Key Leadership

The leadership team at Chandra Bhagat Pharma Limited comprises:

Hemant Chandravadan Bhagat: Chairman and Managing Director, appointed on March 10, 2003.

Prachi Pranav Bhagat: Chief Financial Officer and Executive Director, appointed on August 31, 2019.

Pranav Hemant Bhagat: Whole-Time Director, appointed on May 17, 2004.

Abha Praveen Doshi: Independent Director, appointed on July 15, 2019.

Ravindra Gajanan Awati: Independent Director, appointed on July 15, 2019.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Chandra Bhagat Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Chandra Bhagat Pharma Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary approvals from the U.S. Food and Drug Administration (FDA) for its formulations, enabling manufacturing through contract manufacturers. Additionally, Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals, facilitating access to these regulated markets.

2Emerging Markets

Chandra Bhagat Pharma Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards for its manufacturing facilities enhances its ability to access these markets, as WHO prequalification is often a prerequisite for entry into many emerging economies.

3Geographic Strategy

Chandra Bhagat Pharma Limited's geographic strategy demonstrates a balanced approach, with a significant portion of its exports directed towards the "Other" category (48.1%), followed by Advanced Oncology (18.3%) and Respiratory & OTC (14.3%). This diversification indicates a strategic focus on various therapeutic areas and regions, mitigating concentration risk. The company's export portfolio includes nine products across six therapeutic categories, reflecting a broad market presence.

Chandra Bhagat Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Chandra Bhagat Pharma Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), allowing for the production of pharmaceutical formulations intended for the U.S. market. The company has also obtained necessary approvals for its formulations, enabling manufacturing through contract manufacturers. While specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's compliance with FDA regulations underscores its commitment to quality and regulatory standards.

2WHO & EU GMP

Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals. This adherence to WHO GMP standards facilitates access to regulated markets and underscores the company's commitment to quality manufacturing practices.

3CDSCO & Indian Regulatory

Chandra Bhagat Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Chandra Bhagat Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products across overlapping therapeutic categories. While specific market share data is not publicly disclosed, the company's focus on critical care and healthcare products positions it to compete effectively in both domestic and international markets. The company's adherence to WHO GMP standards and its established distribution networks enhance its competitive edge.

2Key Differentiators

Chandra Bhagat Pharma Limited's key differentiators include its long-standing presence in the pharmaceutical industry since 1944, a diverse product portfolio spanning various therapeutic categories, and a commitment to quality manufacturing practices as evidenced by sourcing products from WHO GMP-approved facilities. These factors contribute to the company's competitive advantages in the market.

3Strategic Position

Chandra Bhagat Pharma Limited's current strategic direction focuses on the marketing of pharmaceutical critical care and healthcare products, with an emphasis on both domestic and international markets. The company's future outlook includes expanding its product portfolio and enhancing its presence in emerging markets, leveraging its adherence to WHO GMP standards and established distribution networks.

Buyer Due Diligence Brief — Evaluating Chandra Bhagat Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Chandra Bhagat Pharma Limited demonstrates a strong track record in the pharmaceutical industry, with a history of introducing several products for the first time in India, such as Anti-Tetanus Serum, Oral Poliomyelitis Vaccine, Anti Diphtheria Sera, Streptokinase, Measles Vaccine, Meningococcal A + C Vaccine, and Human Diploid Rabies Vaccine. The company's export volume and consistency are supported by its adherence to WHO GMP standards and its established distribution networks. Reliability indicators include compliance with regulatory standards and a diverse product portfolio catering to various therapeutic areas.

2Certifications to Verify

Importers should verify the following certifications when considering products from Chandra Bhagat Pharma Limited:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

WHO GMP Certification: Ensure that products are sourced from facilities with World Health Organization Good Manufacturing Practice approvals.

Frequently Asked Questions — Chandra Bhagat Pharma Limited

How many pharmaceutical products does Chandra Bhagat Pharma Limited export from India?

Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories. The top exports are Immunoglobulin ($950.0K), Trastuzumab ($300.0K), Guaifenesin ($283.1K), Cyclosporine ($156.2K), Warfarin ($139.3K). Total export value is $2.0M.

What is Chandra Bhagat Pharma Limited's total pharmaceutical export value?

Chandra Bhagat Pharma Limited's total pharmaceutical export value is $2.0M, based on 81 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Chandra Bhagat Pharma Limited cover?

Chandra Bhagat Pharma Limited exports across 6 therapeutic categories. The largest are Other (48.1%, 1 products), Advanced Oncology (18.3%, 4 products), Respiratory & OTC (14.3%, 1 products).

Get Full Chandra Bhagat Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.